Invention Grant
- Patent Title: Nrf2 activating compounds and uses thereof
-
Application No.: US15811170Application Date: 2017-11-13
-
Publication No.: US10647697B2Publication Date: 2020-05-12
- Inventor: Matthew Duncton , Rajinder Singh
- Applicant: Rigel Pharmaceuticals, Inc.
- Applicant Address: US CA South San Francisco
- Assignee: Rigel Pharmaceuticals, Inc
- Current Assignee: Rigel Pharmaceuticals, Inc
- Current Assignee Address: US CA South San Francisco
- Agency: Bozicevic, Field & Francis LLP
- Agent Rudy J. Ng
- Main IPC: C07D401/14
- IPC: C07D401/14 ; C07D401/04

Abstract:
Aspects of the present disclosure include compounds that activate Nrf2. Such compounds may find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
Public/Granted literature
- US20180258070A1 Nrf2 Activating Compounds and Uses Thereof Public/Granted day:2018-09-13
Information query